China Feihe Ltd
HKEX:6186
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its 3-Year Average (12.3), the stock would be worth HK$3.11 (11% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 13.8 | HK$3.48 |
0%
|
| 3-Year Average | 12.3 | HK$3.11 |
-11%
|
| 5-Year Average | 10.8 | HK$2.73 |
-22%
|
| Industry Average | 26 | HK$6.56 |
+89%
|
| Country Average | 29.6 | HK$7.48 |
+115%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
HK$30B
|
/ |
Jan 2026
¥1.9B
|
= |
|
|
HK$30B
|
/ |
Dec 2026
¥2.6B
|
= |
|
|
HK$30B
|
/ |
Dec 2027
¥2.7B
|
= |
|
|
HK$30B
|
/ |
Dec 2028
¥2.6B
|
= |
|
|
HK$30B
|
/ |
Dec 2029
¥3B
|
= |
|
|
HK$30B
|
/ |
Dec 2030
¥3.3B
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| CN |
|
China Feihe Ltd
HKEX:6186
|
30.7B HKD | 13.8 | |
| JP |
G
|
Goyo Foods Industry Co Ltd
TSE:2230
|
53.2T JPY | 540 752.8 | |
| CH |
|
Nestle SA
SIX:NESN
|
203.3B CHF | 22.5 | |
| US |
|
Mondelez International Inc
NASDAQ:MDLZ
|
78.7B USD | 32.1 | |
| FR |
|
Danone SA
PAR:BN
|
42.7B EUR | 23.5 | |
| ZA |
T
|
Tiger Brands Ltd
JSE:TBS
|
47.6B ZAR | 12.5 | |
| US |
|
Hershey Co
NYSE:HSY
|
37B USD | 41.9 | |
| CN |
|
Muyuan Foods Co Ltd
SZSE:002714
|
244.2B CNY | 25 | |
| ZA |
A
|
Avi Ltd
JSE:AVI
|
33.1B ZAR | 12.8 | |
| CN |
|
Foshan Haitian Flavouring and Food Co Ltd
SSE:603288
|
225.7B CNY | 32.1 | |
| CH |
|
Chocoladefabriken Lindt & Spruengli AG
SIX:LISN
|
23.2B CHF | 31.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 17.1 |
| Median | 29.6 |
| 70th Percentile | 57.7 |
| Max | 43 569.3 |
Other Multiples
China Feihe Ltd
Glance View
China Feihe Ltd., a distinguished player in the infant formula industry, traces its roots back to 1962, establishing itself as a pioneer in dairy production in China. Over the decades, the company has morphed from a state-run enterprise into a market leader, capturing the hearts of parents with its deep understanding of nutritional needs and local dietary preferences. Feihe's story is one of strategic evolution—building a robust supply chain, leveraging advanced research, and investing heavily in quality control. Their vertically integrated business model, from dairy farming and production to distribution, ensures a high standard of excellence. With an extensive product portfolio that covers multiple price points and consumer segments, Feihe caters to middle-class desires for health and premium quality, setting itself apart in a market characterized by growing competition and rising consumer expectations. In the bustling and competitive landscape of China's baby formula market, Feihe crafts its narrative by capitalizing on its '100% Made in China' ethos, assuring consumers of quality and safety—a paramount concern given past industry scandals. Operating through a sleek blend of strategic marketing and community trust-building, the company focuses on fostering customer loyalty and brand recognition. By employing state-of-the-art technology and innovation, Feihe develops products that align with the specific health requirements of Chinese infants. This includes formulas enriched with nutrients like DHA and ARA, mimicking the composition of breast milk, and featuring localized ingredients to ensure assimilation and growth. Feihe continues to elevate its brand by expanding its reach to international markets, signifying a forward-looking approach while remaining rooted in its profound local heritage.